Identification

Name
Parecoxib
Accession Number
DB08439
Type
Small Molecule
Groups
Approved
Description

Parecoxib is a water-soluble and injectable prodrug of valdecoxib. It is marketed as Dynastat in the European Union. Parecoxib is a COX2 selective inhibitor in the same category as celecoxib (Celebrex) and rofecoxib (Vioxx). As it is injectable, it can be used perioperatively when patients are unable to take oral medications. It is approved through much of Europe for short term perioperative pain control much in the same way ketorolac (Toradol) is used in the United States. In 2005, the U.S. Food and Drug Administration (FDA) issued a letter of non-approval for parecoxib in the United States.

Structure
Thumb
Synonyms
Not Available
External IDs
SC 69124 / SC-69124
Product Ingredients
IngredientUNIICASInChI Key
Parecoxib sodiumEB87433V6F 198470-85-8HQPVVKXJNZEAFW-UHFFFAOYSA-M
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DynastatInjection, powder, for solution40 mgIntramuscular; IntravenousPfizer2002-03-22Not applicableEu
DynastatInjection, powder, for solution40 mgIntramuscular; IntravenousPfizer2002-03-22Not applicableEu
DynastatInjection, powder, for solution40 mgIntramuscular; IntravenousPfizer2002-03-22Not applicableEu
DynastatInjection, powder, for solution40 mgIntramuscular; IntravenousPfizer2002-03-22Not applicableEu
International/Other Brands
Dynastat
Categories
UNII
9TUW81Y3CE
CAS number
198470-84-7
Weight
Average: 370.422
Monoisotopic: 370.098727764
Chemical Formula
C19H18N2O4S
InChI Key
TZRHLKRLEZJVIJ-UHFFFAOYSA-N
InChI
InChI=1S/C19H18N2O4S/c1-3-17(22)21-26(23,24)16-11-9-14(10-12-16)18-13(2)25-20-19(18)15-7-5-4-6-8-15/h4-12H,3H2,1-2H3,(H,21,22)
IUPAC Name
N-[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonyl]propanamide
SMILES
CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C1=C(C)ON=C1C1=CC=CC=C1

Pharmacology

Indication

Used for short term perioperative pain control.

Structured Indications
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
AProstaglandin G/H synthase 2
inhibitor
Human
ULactotransferrinNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

98%

Metabolism

Hepatic. Metabolized primarily via CYP3A4 and 2C9 to valdecoxib and propionic acid.

Route of elimination
Not Available
Half life

22 minutes (parecoxib); 8 hours (valdecoxib)

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Parecoxib is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Parecoxib is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Parecoxib is combined with 5-androstenedione.Experimental, Illicit
AbciximabParecoxib may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe metabolism of Parecoxib can be decreased when combined with Abiraterone.Approved
AcebutololParecoxib may decrease the antihypertensive activities of Acebutolol.Approved
AcenocoumarolParecoxib may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Parecoxib.Approved, Vet Approved
AclarubicinParecoxib may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AlaproclateAlaproclate may increase the antiplatelet activities of Parecoxib.Experimental
AlclometasoneThe risk or severity of adverse effects can be increased when Parecoxib is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Parecoxib is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Parecoxib is combined with Alendronic acid.Approved
AliskirenParecoxib may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololParecoxib may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Parecoxib.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Parecoxib is combined with Amcinonide.Approved
AmikacinParecoxib may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideParecoxib may decrease the antihypertensive activities of Amiloride.Approved
AmiodaroneThe serum concentration of Parecoxib can be increased when it is combined with Amiodarone.Approved, Investigational
AmrubicinParecoxib may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodParecoxib may increase the anticoagulant activities of Ancrod.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Parecoxib is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Parecoxib is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Parecoxib is combined with anecortave acetate.Investigational
annamycinParecoxib may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
Antithrombin III humanParecoxib may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanParecoxib may increase the anticoagulant activities of Apixaban.Approved
ApramycinParecoxib may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
AprepitantThe serum concentration of Parecoxib can be increased when it is combined with Aprepitant.Approved, Investigational
ArbekacinParecoxib may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinParecoxib may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanParecoxib may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololParecoxib may decrease the antihypertensive activities of Arotinolol.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Parecoxib is combined with Atamestane.Investigational
AtazanavirThe serum concentration of Parecoxib can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololParecoxib may decrease the antihypertensive activities of Atenolol.Approved
AtomoxetineThe metabolism of Parecoxib can be decreased when combined with Atomoxetine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Parecoxib.Approved
BalsalazideParecoxib may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminParecoxib may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Parecoxib is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololParecoxib may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinParecoxib may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Parecoxib.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Parecoxib.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Parecoxib.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Parecoxib is combined with Betamethasone.Approved, Vet Approved
BetaxololParecoxib may decrease the antihypertensive activities of Betaxolol.Approved
BevantololParecoxib may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Parecoxib.Approved, Investigational
BisoprololParecoxib may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinParecoxib may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Parecoxib can be increased when it is combined with Boceprevir.Withdrawn
BopindololParecoxib may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe metabolism of Parecoxib can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Parecoxib can be decreased when it is combined with Bosentan.Approved, Investigational
BucindololParecoxib may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Parecoxib is combined with Budesonide.Approved
BufuralolParecoxib may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideParecoxib may decrease the diuretic activities of Bumetanide.Approved
BupranololParecoxib may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Parecoxib.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Parecoxib.Experimental
CapecitabineThe serum concentration of Parecoxib can be increased when it is combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Parecoxib.Approved
CarbamazepineThe metabolism of Parecoxib can be increased when combined with Carbamazepine.Approved, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Parecoxib.Approved
CarteololParecoxib may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolParecoxib may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CeliprololParecoxib may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Parecoxib can be increased when it is combined with Ceritinib.Approved
CertoparinParecoxib may increase the anticoagulant activities of Certoparin.Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Parecoxib.Approved, Vet Approved
ChlorotrianiseneParecoxib may increase the thrombogenic activities of Chlorotrianisene.Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Parecoxib.Approved
CholecalciferolThe metabolism of Parecoxib can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Parecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Parecoxib is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Parecoxib.Approved
CinoxacinParecoxib may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CitalopramCitalopram may increase the antiplatelet activities of Parecoxib.Approved
Citric AcidParecoxib may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClarithromycinThe serum concentration of Parecoxib can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Parecoxib can be decreased when combined with Clemastine.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Parecoxib is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Parecoxib is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Parecoxib is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Parecoxib is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Parecoxib is combined with Clodronic Acid.Approved, Investigational, Vet Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Parecoxib.Vet Approved
CloranololParecoxib may decrease the antihypertensive activities of Cloranolol.Experimental
ClorindioneParecoxib may increase the anticoagulant activities of Clorindione.Experimental
ClotrimazoleThe metabolism of Parecoxib can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Parecoxib can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Parecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Parecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Parecoxib can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensParecoxib may increase the thrombogenic activities of Conjugated estrogens.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Parecoxib is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Parecoxib is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Parecoxib is combined with Cortisone acetate.Approved
CrisaboroleThe metabolism of Parecoxib can be decreased when combined with Crisaborole.Approved
CrizotinibThe metabolism of Parecoxib can be decreased when combined with Crizotinib.Approved
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Parecoxib.Experimental
CyclosporineParecoxib may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateParecoxib may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Parecoxib can be decreased when it is combined with Dabrafenib.Approved
DaidzeinParecoxib may increase the thrombogenic activities of Daidzein.Experimental
DalteparinParecoxib may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidParecoxib may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapoxetineDapoxetine may increase the antiplatelet activities of Parecoxib.Investigational
DarexabanParecoxib may increase the anticoagulant activities of Darexaban.Investigational
DarunavirThe serum concentration of Parecoxib can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Parecoxib can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinParecoxib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe serum concentration of Parecoxib can be decreased when it is combined with Deferasirox.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Parecoxib.Experimental
DelavirdineThe serum concentration of Parecoxib can be increased when it is combined with Delavirdine.Approved
DesirudinParecoxib may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Parecoxib is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Parecoxib is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Parecoxib is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Parecoxib is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Parecoxib.Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Parecoxib is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Parecoxib is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Parecoxib.Approved
DextranParecoxib may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Parecoxib may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Parecoxib may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Parecoxib may increase the anticoagulant activities of Dextran 75.Approved
DextromethorphanThe serum concentration of Dextromethorphan can be increased when it is combined with Parecoxib.Approved
DibekacinParecoxib may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DicoumarolParecoxib may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolParecoxib may increase the thrombogenic activities of Dienestrol.Approved
DiethylstilbestrolParecoxib may increase the thrombogenic activities of Diethylstilbestrol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Parecoxib is combined with Diflorasone.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Parecoxib is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Parecoxib is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Parecoxib.Approved
DihydroergotamineThe metabolism of Parecoxib can be decreased when combined with Dihydroergotamine.Approved
DihydrostreptomycinParecoxib may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DiltiazemThe metabolism of Parecoxib can be decreased when combined with Diltiazem.Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Parecoxib.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Parecoxib.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Parecoxib.Approved
DiphenadioneParecoxib may increase the anticoagulant activities of Diphenadione.Experimental
DosulepinThe serum concentration of Parecoxib can be increased when it is combined with Dosulepin.Approved
DoxorubicinParecoxib may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DoxycyclineThe metabolism of Parecoxib can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Parecoxib can be decreased when combined with Dronedarone.Approved
DrospirenoneParecoxib may increase the hyperkalemic activities of Drospirenone.Approved
DuloxetineDuloxetine may increase the antiplatelet activities of Parecoxib.Approved
Edetic AcidParecoxib may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanParecoxib may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe metabolism of Parecoxib can be decreased when combined with Efavirenz.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Parecoxib.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Parecoxib.Approved
EnoxacinParecoxib may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinParecoxib may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Parecoxib.Experimental
EnzalutamideThe serum concentration of Parecoxib can be decreased when it is combined with Enzalutamide.Approved
EpanololParecoxib may decrease the antihypertensive activities of Epanolol.Experimental
EpimestrolParecoxib may increase the thrombogenic activities of Epimestrol.Experimental
EpirubicinParecoxib may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneParecoxib may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Parecoxib.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Parecoxib.Approved
EquileninThe risk or severity of adverse effects can be increased when Parecoxib is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Parecoxib is combined with Equilin.Approved
EquolParecoxib may increase the thrombogenic activities of Equol.Investigational
ErythromycinThe metabolism of Parecoxib can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramEscitalopram may increase the antiplatelet activities of Parecoxib.Approved, Investigational
EsmololParecoxib may decrease the antihypertensive activities of Esmolol.Approved
EstradiolParecoxib may increase the thrombogenic activities of Estradiol.Approved, Investigational, Vet Approved
EstriolParecoxib may increase the thrombogenic activities of Estriol.Approved, Vet Approved
EstroneParecoxib may increase the thrombogenic activities of Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Parecoxib is combined with Estrone sulfate.Approved
Etacrynic acidParecoxib may decrease the diuretic activities of Etacrynic acid.Approved
Ethinyl EstradiolParecoxib may increase the thrombogenic activities of Ethinyl Estradiol.Approved
Ethyl biscoumacetateParecoxib may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Parecoxib is combined with Etidronic acid.Approved
EtoperidoneEtoperidone may increase the antiplatelet activities of Parecoxib.Approved
EtravirineThe metabolism of Parecoxib can be decreased when combined with Etravirine.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Parecoxib.Vet Approved
Ferulic acidParecoxib may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Parecoxib.Approved
FleroxacinParecoxib may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Parecoxib.Approved, Withdrawn
FloxuridineThe serum concentration of Parecoxib can be increased when it is combined with Floxuridine.Approved
fluasteroneThe risk or severity of adverse effects can be increased when Parecoxib is combined with fluasterone.Investigational
FluconazoleThe serum concentration of Parecoxib can be increased when it is combined with Fluconazole.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Parecoxib is combined with Fludrocortisone.Approved
FluindioneParecoxib may increase the anticoagulant activities of Fluindione.Investigational
FlumequineParecoxib may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Parecoxib is combined with Flumethasone.Approved, Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Parecoxib is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Parecoxib is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Parecoxib is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Parecoxib.Approved
FluorouracilThe serum concentration of Parecoxib can be increased when it is combined with Fluorouracil.Approved
FluoxetineFluoxetine may increase the antiplatelet activities of Parecoxib.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Parecoxib is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Parecoxib is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Parecoxib.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Parecoxib is combined with Flurandrenolide.Approved
FluvastatinThe metabolism of Parecoxib can be decreased when combined with Fluvastatin.Approved
FluvoxamineFluvoxamine may increase the antiplatelet activities of Parecoxib.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Parecoxib.Approved, Nutraceutical, Vet Approved
FondaparinuxParecoxib may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumParecoxib may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Parecoxib.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Parecoxib is combined with Formestane.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Parecoxib can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Parecoxib can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Parecoxib.Approved
FosphenytoinThe metabolism of Parecoxib can be increased when combined with Fosphenytoin.Approved
FramycetinParecoxib may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideParecoxib may decrease the diuretic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Parecoxib can be increased when it is combined with Fusidic Acid.Approved
GabexateParecoxib may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinParecoxib may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinParecoxib may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Parecoxib.Approved, Withdrawn
GemfibrozilThe serum concentration of Parecoxib can be increased when it is combined with Gemfibrozil.Approved
GemifloxacinParecoxib may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinParecoxib may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GenisteinParecoxib may increase the thrombogenic activities of Genistein.Investigational
GentamicinParecoxib may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AParecoxib may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Parecoxib may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinParecoxib may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Parecoxib is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Parecoxib is combined with HE3286.Investigational
HeparinParecoxib may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolParecoxib may increase the thrombogenic activities of Hexestrol.Withdrawn
HydralazineParecoxib may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Parecoxib.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Parecoxib is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Parecoxib.Approved
Hygromycin BParecoxib may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Parecoxib is combined with Ibandronate.Approved, Investigational
IdarubicinParecoxib may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxParecoxib may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Parecoxib.Approved, Investigational
ImatinibThe metabolism of Parecoxib can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Parecoxib.Investigational
IndalpineIndalpine may increase the antiplatelet activities of Parecoxib.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Parecoxib.Approved
IndenololParecoxib may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Parecoxib can be increased when it is combined with Indinavir.Approved
INNO-206Parecoxib may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe metabolism of Parecoxib can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Parecoxib can be decreased when combined with Isavuconazonium.Approved, Investigational
IsepamicinParecoxib may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsradipineThe metabolism of Parecoxib can be decreased when combined with Isradipine.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Parecoxib is combined with Istaroxime.Investigational
ItraconazoleThe serum concentration of Parecoxib can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Parecoxib can be increased when it is combined with Ivacaftor.Approved
KanamycinParecoxib may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KetoconazoleThe serum concentration of Parecoxib can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolParecoxib may decrease the antihypertensive activities of Labetalol.Approved
LandiololParecoxib may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Parecoxib.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Parecoxib.Investigational
LeflunomideThe metabolism of Parecoxib can be decreased when combined with Leflunomide.Approved, Investigational
LepirudinParecoxib may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanParecoxib may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololParecoxib may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinParecoxib may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Parecoxib.Approved
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Parecoxib.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Parecoxib.Approved, Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Parecoxib.Approved
LobeglitazoneThe metabolism of Parecoxib can be decreased when combined with Lobeglitazone.Approved
LopinavirThe serum concentration of Parecoxib can be increased when it is combined with Lopinavir.Approved
LosartanThe metabolism of Parecoxib can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Parecoxib can be decreased when combined with Lovastatin.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Parecoxib.Approved, Investigational
LuliconazoleThe serum concentration of Parecoxib can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Parecoxib can be decreased when it is combined with Lumacaftor.Approved
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Parecoxib.Vet Approved
ManidipineThe metabolism of Parecoxib can be decreased when combined with Manidipine.Approved
ME-609The risk or severity of adverse effects can be increased when Parecoxib is combined with ME-609.Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Parecoxib is combined with Medrysone.Approved
MelagatranParecoxib may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Parecoxib is combined with Melengestrol.Vet Approved
MepindololParecoxib may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineParecoxib may increase the nephrotoxic activities of Mesalazine.Approved
MestranolParecoxib may increase the thrombogenic activities of Mestranol.Approved
MethallenestrilParecoxib may increase the thrombogenic activities of Methallenestril.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Parecoxib.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Parecoxib.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Parecoxib is combined with Methylprednisolone.Approved, Vet Approved
MetipranololParecoxib may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Parecoxib.Approved
MetoprololParecoxib may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideParecoxib may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinParecoxib may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MidostaurinThe serum concentration of Parecoxib can be increased when it is combined with Midostaurin.Approved
MifepristoneThe serum concentration of Parecoxib can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the antiplatelet activities of Parecoxib.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Parecoxib.Approved
MitotaneThe serum concentration of Parecoxib can be decreased when it is combined with Mitotane.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Parecoxib.Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Parecoxib.Approved
MoxestrolParecoxib may increase the thrombogenic activities of Moxestrol.Experimental
NadololParecoxib may decrease the antihypertensive activities of Nadolol.Approved
NadroparinParecoxib may increase the anticoagulant activities of Nadroparin.Approved
NafamostatParecoxib may increase the anticoagulant activities of Nafamostat.Approved, Investigational
Nalidixic AcidParecoxib may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NCX 1022The risk or severity of adverse effects can be increased when Parecoxib is combined with NCX 1022.Investigational
NeamineParecoxib may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NefazodoneThe serum concentration of Parecoxib can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Parecoxib can be increased when it is combined with Nelfinavir.Approved
NemonoxacinParecoxib may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinParecoxib may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NetilmicinParecoxib may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NetupitantThe serum concentration of Parecoxib can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Parecoxib can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Parecoxib can be increased when it is combined with Nicardipine.Approved
NilotinibThe metabolism of Parecoxib can be decreased when combined with Nilotinib.Approved, Investigational
NorfloxacinParecoxib may increase the neuroexcitatory activities of Norfloxacin.Approved
OlaparibThe metabolism of Parecoxib can be decreased when combined with Olaparib.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Parecoxib is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Parecoxib.Approved, Investigational
OlsalazineParecoxib may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Parecoxib is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Parecoxib.Investigational
OmeprazoleThe metabolism of Parecoxib can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Parecoxib can be increased when it is combined with Osimertinib.Approved
OtamixabanParecoxib may increase the anticoagulant activities of Otamixaban.Investigational
Oxolinic acidParecoxib may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololParecoxib may decrease the antihypertensive activities of Oxprenolol.Approved
PalbociclibThe serum concentration of Parecoxib can be increased when it is combined with Palbociclib.Approved
PamidronateThe risk or severity of adverse effects can be increased when Parecoxib is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Parecoxib is combined with Paramethasone.Approved
ParomomycinParecoxib may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParoxetineParoxetine may increase the antiplatelet activities of Parecoxib.Approved, Investigational
PazufloxacinParecoxib may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinParecoxib may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololParecoxib may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
PentobarbitalThe metabolism of Parecoxib can be increased when combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateParecoxib may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Parecoxib.Approved
PhenindioneParecoxib may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Parecoxib can be increased when combined with Phenobarbital.Approved
PhenprocoumonParecoxib may increase the anticoagulant activities of Phenprocoumon.Approved
PhenytoinThe metabolism of Parecoxib can be increased when combined with Phenytoin.Approved, Vet Approved
PindololParecoxib may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidParecoxib may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinParecoxib may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideParecoxib may decrease the diuretic activities of Piretanide.Experimental
Piromidic acidParecoxib may increase the neuroexcitatory activities of Piromidic acid.Experimental
PlazomicinParecoxib may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinParecoxib may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
Polyestradiol phosphateParecoxib may increase the thrombogenic activities of Polyestradiol phosphate.Approved
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Parecoxib.Approved
PosaconazoleThe serum concentration of Parecoxib can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PractololParecoxib may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Parecoxib.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Parecoxib is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Parecoxib is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Parecoxib is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Parecoxib is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Parecoxib is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Parecoxib is combined with Pregnenolone.Experimental
PrimidoneThe metabolism of Parecoxib can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Parecoxib can be increased when it is combined with Probenecid.Approved
PromestrieneParecoxib may increase the thrombogenic activities of Promestriene.Investigational
PropranololParecoxib may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Parecoxib.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Parecoxib.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Parecoxib.Vet Approved
Protein CParecoxib may increase the anticoagulant activities of Protein C.Approved
Protein S humanParecoxib may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeParecoxib may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinParecoxib may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PuromycinParecoxib may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Parecoxib can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Parecoxib.Approved, Investigational
QuinestrolParecoxib may increase the thrombogenic activities of Quinestrol.Approved
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Parecoxib.Approved
QuinineThe metabolism of Parecoxib can be decreased when combined with Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Parecoxib.Approved
RanolazineThe metabolism of Parecoxib can be decreased when combined with Ranolazine.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Parecoxib.Approved
ReviparinParecoxib may increase the anticoagulant activities of Reviparin.Approved
RibostamycinParecoxib may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RifabutinThe metabolism of Parecoxib can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Parecoxib can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Parecoxib can be increased when combined with Rifapentine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Parecoxib is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Parecoxib is combined with Risedronate.Approved, Investigational
RitonavirThe serum concentration of Parecoxib can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanParecoxib may increase the anticoagulant activities of Rivaroxaban.Approved
RosoxacinParecoxib may increase the neuroexcitatory activities of Rosoxacin.Approved
RufloxacinParecoxib may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinParecoxib may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Parecoxib.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Parecoxib.Experimental
SaquinavirThe serum concentration of Parecoxib can be increased when it is combined with Saquinavir.Approved, Investigational
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Parecoxib.Investigational
SecobarbitalThe metabolism of Parecoxib can be increased when combined with Secobarbital.Approved, Vet Approved
SecoisolariciresinolParecoxib may increase the thrombogenic activities of Secoisolariciresinol.Investigational
SertralineSertraline may increase the antiplatelet activities of Parecoxib.Approved
SildenafilThe metabolism of Parecoxib can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Parecoxib can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Parecoxib can be increased when it is combined with Simeprevir.Approved
SisomicinParecoxib may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinParecoxib may increase the neuroexcitatory activities of Sitafloxacin.Experimental
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Parecoxib.Approved
SorafenibThe metabolism of Parecoxib can be decreased when combined with Sorafenib.Approved, Investigational
SotalolParecoxib may decrease the antihypertensive activities of Sotalol.Approved
SP1049CParecoxib may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinParecoxib may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinParecoxib may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Parecoxib.Approved
SpironolactoneParecoxib may decrease the antihypertensive activities of Spironolactone.Approved
St. John's WortThe serum concentration of Parecoxib can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Parecoxib can be increased when it is combined with Stiripentol.Approved
StreptomycinParecoxib may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinParecoxib may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfadiazineThe serum concentration of Parecoxib can be increased when it is combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Parecoxib can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe serum concentration of Parecoxib can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SulodexideParecoxib may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Parecoxib.Investigational
Synthetic Conjugated Estrogens, AParecoxib may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BParecoxib may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TacrolimusParecoxib may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Parecoxib.Approved
TalinololParecoxib may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Parecoxib.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Parecoxib.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Parecoxib is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Parecoxib is combined with Technetium Tc-99m medronate.Approved
TelaprevirThe serum concentration of Parecoxib can be increased when it is combined with Telaprevir.Withdrawn
TelithromycinThe serum concentration of Parecoxib can be increased when it is combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Parecoxib.Approved, Investigational
TemafloxacinParecoxib may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Parecoxib.Experimental, Investigational
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Parecoxib is combined with Tenofovir disoproxil.Approved, Investigational
TertatololParecoxib may decrease the antihypertensive activities of Tertatolol.Experimental
TiboloneParecoxib may increase the thrombogenic activities of Tibolone.Approved
TicagrelorThe metabolism of Parecoxib can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Parecoxib can be decreased when combined with Ticlopidine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Parecoxib is combined with Tiludronic acid.Approved, Vet Approved
TimololParecoxib may decrease the antihypertensive activities of Timolol.Approved
TioclomarolParecoxib may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Parecoxib is combined with Tixocortol.Approved
TobramycinParecoxib may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TocilizumabThe serum concentration of Parecoxib can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe serum concentration of Parecoxib can be increased when it is combined with Tolbutamide.Approved
TopiroxostatThe metabolism of Parecoxib can be decreased when combined with Topiroxostat.Approved
TorasemideParecoxib may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Parecoxib.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Parecoxib.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Parecoxib.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Parecoxib is combined with Triamcinolone.Approved, Vet Approved
TriamtereneParecoxib may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Parecoxib.Approved, Vet Approved
TrimethoprimThe metabolism of Parecoxib can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrovafloxacinParecoxib may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
TroxerutinParecoxib may increase the anticoagulant activities of Troxerutin.Investigational
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Parecoxib.Approved
Valproic AcidThe metabolism of Parecoxib can be decreased when combined with Valproic Acid.Approved, Investigational
ValrubicinParecoxib may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe metabolism of Parecoxib can be decreased when combined with Valsartan.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Parecoxib.Approved
VenlafaxineVenlafaxine may increase the antiplatelet activities of Parecoxib.Approved
VerapamilThe metabolism of Parecoxib can be decreased when combined with Verapamil.Approved
VoriconazoleThe serum concentration of Parecoxib can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinParecoxib may increase the anticoagulant activities of Warfarin.Approved
XimelagatranParecoxib may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZafirlukastThe metabolism of Parecoxib can be decreased when combined with Zafirlukast.Approved, Investigational
ZeranolParecoxib may increase the thrombogenic activities of Zeranol.Vet Approved
ZimelidineZimelidine may increase the antiplatelet activities of Parecoxib.Withdrawn
ZiprasidoneThe metabolism of Parecoxib can be decreased when combined with Ziprasidone.Approved
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Parecoxib.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Parecoxib is combined with Zoledronic acid.Approved
Zoptarelin doxorubicinParecoxib may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinParecoxib may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
Not Available
External Links
KEGG Drug
D02709
PubChem Compound
119828
PubChem Substance
99444910
ChemSpider
106990
ChEBI
73038
ChEMBL
CHEMBL1206690
PharmGKB
PA166049193
HET
PXB
Wikipedia
Parecoxib
ATC Codes
M01AH04 — Parecoxib
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedPreventionPost-Operative Pain / Shoulder Pain1
2, 3CompletedNot AvailablePOSTOPERATIVE ANALGESIA FOR TKA PARECOXIB/CFB1
3CompletedTreatmentPostoperative pain1
3Not Yet RecruitingTreatmentParecoxib / Rib Fractures1
3RecruitingTreatmentLiver Cancer / Postoperative pain1
3TerminatedTreatmentColic1
3TerminatedTreatmentPain1
4CompletedBasic ScienceSecondary Hyperalgesia1
4CompletedPreventionPostoperative Pain Management, Pain Threshold, Shoulder Pain, Laparoscopies1
4CompletedPreventionPostoperative pain1
4CompletedSupportive CarePostoperative pain1
4CompletedTreatmentAnaesthesia1
4CompletedTreatmentInflammatory Reaction / Pain1
4CompletedTreatmentPain1
4CompletedTreatmentPost-Operative Pain1
4CompletedTreatmentPostoperative Shivering1
4CompletedTreatmentPostoperative pain2
4CompletedTreatmentRupture of Anterior Cruciate Ligament1
4TerminatedTreatmentPost Surgical Pain1
4TerminatedTreatmentPostoperative pain1
4Unknown StatusSupportive CareGastrointestinal Cancers1
4Unknown StatusTreatmentEmergence Delirium / Postoperative pain1
4Unknown StatusTreatmentHepatic Hemangioma Located in the Right Liver / Laparotomy Surgery1
4WithdrawnTreatmentPostoperative pain1
Not AvailableCompletedNot AvailableHepatocellular,Carcinoma1
Not AvailableCompletedBasic SciencePlatelet Aggregation1
Not AvailableCompletedTreatmentAnti-Inflammatory Agents, Non-Steroidal / Laparoscopy / Postoperative pain1
Not AvailableCompletedTreatmentBenign Female Reproductive System Neoplasm1
Not AvailableCompletedTreatmentPostoperative pain1
Not AvailableNo Longer AvailableNot AvailableComplex Regional Pain Syndrome Type II1
Not AvailableUnknown StatusTreatmentPostoperative pain1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, powder, for solutionIntramuscular; Intravenous40 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0162 mg/mLALOGPS
logP3.42ALOGPS
logP3.51ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)4.24ChemAxon
pKa (Strongest Basic)0.42ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area89.27 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity98.9 m3·mol-1ChemAxon
Polarizability38 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.8694
Caco-2 permeable-0.644
P-glycoprotein substrateNon-substrate0.8144
P-glycoprotein inhibitor INon-inhibitor0.7995
P-glycoprotein inhibitor IINon-inhibitor0.8537
Renal organic cation transporterNon-inhibitor0.8889
CYP450 2C9 substrateNon-substrate0.702
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateNon-substrate0.6159
CYP450 1A2 substrateNon-inhibitor0.8459
CYP450 2C9 inhibitorInhibitor0.801
CYP450 2D6 inhibitorNon-inhibitor0.8356
CYP450 2C19 inhibitorInhibitor0.6608
CYP450 3A4 inhibitorNon-inhibitor0.5165
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8722
Ames testNon AMES toxic0.7504
CarcinogenicityCarcinogens 0.5086
BiodegradationNot ready biodegradable0.9899
Rat acute toxicity2.2665 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9874
hERG inhibition (predictor II)Non-inhibitor0.9083
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of chemical entities known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
Kingdom
Chemical entities
Super Class
Organic compounds
Class
Benzenoids
Sub Class
Benzene and substituted derivatives
Direct Parent
Benzenesulfonamides
Alternative Parents
Benzenesulfonyl compounds / Sulfonyls / Organosulfonic acids and derivatives / Isoxazoles / Heteroaromatic compounds / Oxacyclic compounds / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Organonitrogen compounds
show 2 more
Substituents
Benzenesulfonamide / Benzenesulfonyl group / Azole / Isoxazole / Organic sulfonic acid or derivatives / Organosulfonic acid or derivatives / Heteroaromatic compound / Sulfonyl / Oxacycle / Organoheterocyclic compound
show 10 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
sulfonamide, isoxazoles (CHEBI:73038 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Talley JJ, Bertenshaw SR, Brown DL, Carter JS, Graneto MJ, Kellogg MS, Koboldt CM, Yuan J, Zhang YY, Seibert K: N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration. J Med Chem. 2000 May 4;43(9):1661-3. [PubMed:10794682 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serine-type endopeptidase activity
Specific Function
Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate.Lactotransferrin is a major iron-binding and multifu...
Gene Name
LTF
Uniprot ID
P02788
Uniprot Name
Lactotransferrin
Molecular Weight
78181.225 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Ibrahim AE, Feldman J, Karim A, Kharasch ED: Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. Anesthesiology. 2003 Apr;98(4):853-61. [PubMed:12657846 ]
  2. DrugBank Entry Valdecoxib (is a prodrug of Valdecoxib) [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. DrugBank Entry Valdecoxib (is a prodrug of Valdecoxib) [Link]

Drug created on September 15, 2010 15:31 / Updated on October 02, 2017 06:06